Background: Preoperative thrombocytosis (PTC) is frequently observed in various solid malignancies and often associated with an unfavourable oncological outcome. Objectives: The aim of this study was to investigate the influence of PTC in patients undergoing radical cystectomy (RC) for urothelial carcinoma (UC) of the bladder on the oncological prognosis and additionally on perioperative blood transfusions (PBT). Method: A retrospective analysis of 866 patients undergoing RC in a tertiary care centre was performed. PTC was defined as a platelet count >400 G/L. A chi-square test and Mann-Whitney test were used to investigate the association of PTC with categorical clinicopathological variables. A logrank test and multivariable Cox regression analyses were used to assess the association of PTC with cancer-specific survival. Results: PTC was detected in 8% (n = 67) of the patients and was significantly associated with muscle invasion (p = 0.004), advanced tumour stages (p = 0.003) and nodal metastases (p < 0.001) and with a higher rate of PBT (p< 0.001). In the multivariate analysis, PTC was significantly related to poor oncological survival (hazard ratio 2.23, 95% CI 1.51–3.30, p < 0.001). Conclusion: PTC is significantly associated with an impaired oncological outcome in patients undergoing RC for UC. PTC therefore represents an independent and easy to determine prognostic parameter for patients’ oncological outcome. Intriguingly, PTC is significantly associated with an increased rate of PBT.

Keywords:
Bladder cancer, Radical cystectomy, Thrombocytosis, Preoperative platelet count
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
Eur J Cancer
. 2013 Apr;49(6):1374–403.
2.
Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend?
J Urol
. 2001 Jan;165(1):47–50.
3.
Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. EAU-Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS).
Eur Urol
. 2015;41:105–12.
4.
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, James N, et al. Muscle-invasive and metastatic bladder cancer. 2015.
5.
Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder.
World J Urol
. 2006 Aug;24(3):305–14.
6.
Grimm T, Buchner A, Schneevoigt B, Kretschmer A, Apfelbeck M, Grabbert M, et al. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.
World J Urol
. 2016 May;34(5):703–8.
7.
Schulz GB, Grimm T, Buchner A, Jokisch F, Grabbert M, Schneevoigt BS, et al. Prognostic value of the preoperative platelet-to-leukocyte ratio for oncologic outcomes in patients undergoing radical cystectomy for bladder cancer.
Clin Genitourin Cancer
. 2017 Dec;15(6):e915–21.
8.
Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer.
World J Surg
. 2012 Jan;36(1):192–200.
9.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer.
N Engl J Med
. 2012 Feb;366(7):610–8.
10.
O’Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy.
J Urol
. 2002 Oct;168(4 Pt 1):1378–80.
11.
Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer.
Eur Respir J
. 1996 Sep;9(9):1826–30.
12.
Gakis G, Todenhöfer T, Renninger M, Schilling D, Sievert KD, Schwentner C, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
BJU Int
. 2011 Dec;108(11):1800–5.
13.
Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, et al. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.
Anticancer Res
. 2014 Jun;34(6):3225–30.
14.
Buchner A, Grimm T, Schneevoigt BS, Wittmann G, Kretschmer A, Jokisch F, et al. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage.
Scand J Urol
. 2017 Apr;51(2):130–6.
15.
Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Rouprêt M, et al.; UTUC Collaboration. Predictive and prognostic value of preoperative thrombocytosis in upper tract urothelial carcinoma.
Clin Genitourin Cancer
. 2017 Dec;15(6):e1039–45.
16.
Voutsadakis IA. Thrombocytosis as a prognostic marker in gastrointestinal cancers.
World J Gastrointest Oncol
. 2014 Feb;6(2):34–40.
17.
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Clin Cancer Res
. 2000 Jul;6(7):2702–6.
18.
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis.
Nat Rev Cancer
. 2011 Feb;11(2):123–34.
19.
Pinedo HM, Verheul HM, D’Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis?
Lancet
. 1998 Nov;352(9142):1775–7.
20.
Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited.
Cancer Metastasis Rev
. 2014 Mar;33(1):231–69.
21.
Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic–progress and pitfalls.
Nat Rev Clin Oncol
. 2013 Mar;10(3):169–79.
22.
Todenhöfer T, Renninger M, Schwentner C, Stenzl A, Gakis G. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
BJU Int
. 2012 Dec;110(11 Pt B):E533–40.
23.
Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
J Urol
. 2006 Jun;175(6):2048–53.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.